Eli Lilly is drawing attention across 1 news outlets right now. The reports below are the current coverage, newest first.
BusinessCNBC
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.